XOMA Royalty Corp: 5%+ holders

As of November 8, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of XOMA Royalty Corp. The largest reported stake is Ligand Pharmaceuticals Incorporated's, at 47%. 18 filings are on record since July 29, 2025 (Schedule 13D, May 1, 2026).

Ligand Pharmaceuticals Incorporated also filed stake reports on 1 other company ↓

Sell to companies like XOMA Royalty Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-07 · Reporting person: Fmr LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-07
• Filing 2026-08-07 · Reporting person: Morgan Stanley · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-07
• Filed 2026-08-07 · Holder: Morgan Stanley · Percent: 9.5% · SCHEDULE 13G/A
• Filed 2026-08-06 · Holder: Fmr LLC · Percent: 9.1% · SCHEDULE 13G/A
• Filing 2026-07-31 · Reporting person: Vanguard Capital Management · Sole voting: 66,658 · Shared voting: 0 · Sole dispositive: 571,823 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-31

XOMA Royalty Corp has 18 Schedule 13D or 13G filings on record since 2025-07-29. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind XOMA Royalty Corp and the warning signs.

See XOMA Royalty Corp's free Snapshot Watch XOMA Royalty Corp: email me the next time it files something

Free to see. No signup.

Keep reading

More on XOMA Royalty Corp and the records around it.

Companies that share a holder

• Ligand Pharmaceuticals Incorporated also filed stake reports on 1 other company: Pelthos Therapeutics Inc. (Nov 2026)
• Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
• BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)

Want the whole picture on XOMA Royalty Corp?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on XOMA Royalty Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on XOMA Royalty Corp covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   21 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies XOMA Royalty Corp by CUSIP 98419J206 and gives its principal executive office as 2200 POWELL STREET, SUITE 310, EMERYVILLE, CA 94608 (SCHEDULE 13G/A, 2026-08-07).

Source of funds (Item 3)

Item 3 is hereby amended and restated to read as follows: As described in Items 4 and 5 below, the Reporting Persons no longer beneficially own any Shares.Biotechnology Value Fund L P, SCHEDULE 13D/A, 2026-07-16

Purpose of Transaction (Item 4)

Biotechnology Value Fund L P

Item 4 is hereby amended to add the following: On July 14, 2026, the Issuer consummated the Merger with Ligand Pharmaceuticals Incorporated ("Parent") in accordance with the terms of that certain Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"). Pursuant to the Merger Agreement, Flex Merger Sub, Inc., a wholly owned subsidiary of Parent merged with and into XOMA Royalty Holdings Corporation ("HoldCo") (the "Merger"), with HoldCo surviving the Merger as a wholly owned subsidiary of Parent and the Issuer effected the Holding Company Reorganization (as defined in the Merger Agreement) and the Merger. Pursuant to the Merger Agreement and various other transactions, each Share was automatically converted into the right to receive (i) $39.00 per Share in cash, plus (ii) an amount of contingent value rights representing a right to receive potential cash payments. Accordingly, the Reporting Persons ceased to beneficially own any securities of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2026-07-16

Ligand Pharmaceuticals Incorporated

Items 3 and 5 are incorporated by reference in this Item 4 as if fully set forth herein. The purpose of the Merger (as defined below) is for Ligand to acquire control of, and the entire equity interest in, the Issuer. Merger Agreement On April 27, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Ligand and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Ligand ("Merger Sub") pursuant to which, and upon the terms and subject to the conditions thereof, including, without limitation, effecting the Holding Company Reorganization (as defined below), Merger Sub will merge with and into HoldCo (as defined below) (the "Merger"), with HoldCo surviving the Merger as a wholly owned subsidiary of Ligand. Pursuant to the Merger Agreement, at the time the Merger becomes effective (the "Effective Time"), each share of Common Stock issued and outstanding immediately prior to the Effective Time (other than certain shares of Common Stock to be canceled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) will be automatically converted into the right to receive (i) $39.00 per share in cash, without interest, and subject to deduction for any required withholding tax, plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive contingent payments derived from the CVR Trust's (as defined below) interest in RemainCo LLC (as defined below) in …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-01; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns XOMA Royalty Corp

Who owns XOMA Royalty Corp?

On this page, 2 holders' latest ownership filings report 5% or more of XOMA Royalty Corp: Ligand Pharmaceuticals Incorporated (47%, Schedule 13D, filed 2026-05-01) and Woodline Partners LP (5.4%, Schedule 13G, filed 2026-05-15).

Who are the largest shareholders of XOMA Royalty Corp?

By the share each holder's latest filing reports, the largest holders of XOMA Royalty Corp on this page are Ligand Pharmaceuticals Incorporated (47%) and Woodline Partners LP (5.4%).

When did Ligand Pharmaceuticals Incorporated buy into XOMA Royalty Corp?

The filings give report dates, not purchase dates. The earliest filing from Ligand Pharmaceuticals Incorporated on this page is the Schedule 13D, filed 2026-05-01, reporting 47%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for XOMA Royalty Corp

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for XOMA Royalty Corp. With no account yet, you sign up free and land on the result.

• Get an alert when XOMA Royalty Corp is mentioned again
• Find former XOMA Royalty Corp employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes